Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686).

Abstract

This study was designed to evaluate the toxicity and efficacy of cisplatin and WR-2721 in contrast to cisplatin alone for the therapy of measurable metastatic melanoma. Ninety-four patients with metastatic melanoma were randomized to receive either cisplatin at a dose of 150 mg/m2 and WR-2721 at a dose of 910 mg/m2, or cisplatin alone at a dose of 120 mg/m2… (More)

Topics

Cite this paper

@article{Glover2003PhaseIR, title={Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686).}, author={Donna J. Glover and Joseph G. Ibrahim and John Munn Kirkwood and John Glick and Daniel Karp and James A Stewart and Marian G Ewell and Ernest C. Borden}, journal={Melanoma research}, year={2003}, volume={13 6}, pages={619-26} }